After three dynamic days at CPHI Europe 2025—the world’s leading pharmaceutical sourcing event—Hunan Warrant stood out among global industry leaders with an impressive showcase in Frankfurt, Germany. As a key pharmaceutical manufacturer from Hunan, Warrant captivated the international stage with a specially designed booth featuring a selection of high-value APIs, drawing strong interest from over 150 pharmaceutical companies across the globe.

       CPHI serves as the ultimate barometer for global pharmaceutical trends, and this year’s exhibition gathered more than 62,000 professionals and 2,400 exhibitors from 166 countries. It was the ideal platform for innovation exchange and worldwide partnership building.

At the heart of this global convergence, Hunan Warrant made a powerful statement with a custom-built 30+ square booth. The display vividly illustrated the company’s deep expertise in pharmaceutical R&D and manufacturing, along with its exciting vision for future growth.

Warrant’s exhibition team received widespread recognition from clients across Europe, South America, Southeast Asia, the Middle East, and North Africa. Visitors applauded the company’s pragmatic approach, diverse product portfolio, strong R&D capacity, and end-to-end service solutions. The high-level engagements during the event have paved the way for new orders and expanded global reach—further strengthening Warrant’s role in bringing Hunan’s pharmaceutical innovation to the world.

With a robust portfolio of over 70 high-end APIs, Warrant continues to build its international presence. Three of its key products—Choline Alfoscerate, Ticagrelor, and Tofacitinib Citrate—are already approved in South Korea, while Fosfomycin Trometamol holds certifications in multiple countries. In addition, the company supplies dozens of API intermediates and more than 20 pharmaceutical excipients, reinforcing its integrated supply chain capabilities.

        Looking ahead, Warrant is accelerating the development of its new 230-acre Green Intelligent Manufacturing Base. Designed for an annual output of 3,000 tons of high-end APIs and intermediates, the project has reached a key milestone with several workshops already topped out. Mass production is expected to begin by May 2026. Built to international standards, the facility will comply with stringent regulations including U.S. FDA, EU EMA, and Japan PMDA. Through full international certification, Warrant is poised to significantly boost its global market share and reinforce its position as a world-class API supplier.